Clin Mol Hepatol.  2012 Sep;18(3):272-278. 10.3350/cmh.2012.18.3.272.

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

Affiliations
  • 1Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University College of Medicine, Bucheon, Korea. liverkys@schmc.ac.kr
  • 2Department of Internal Medicine, Soon Chun Hyang University Cheonan Hospital, Soon Chun Hyang University College of Medicine, Cheonan, Korea.
  • 3Department of Internal Medicine, Soon Chun Hyang University Seoul Hospital, Soon Chun Hyang University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND/AIMS
When combined with pegylated interferon alpha-2b (Peg-IFN alpha-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than for patients in Western countries, current guidelines might result in Korean patients being overdosed with RBV.
METHODS
We retrospectively reviewed the medical records of patients with genotype 1 CHC who were treated with Peg-IFN alpha-2b and RBV combination therapy. We divided the patients into groups A (> or =15 mg/kg/day, n=23) and B (<15 mg/kg/day, n=26), given that the standard dose is 15 mg/kg/day. The clinical course in terms of the virologic response, adverse events, and dose modification rate was compared between the two groups after therapy completion.
RESULTS
The early response rates (92.0% vs. 83.3%, P=0.634) and sustained virologic response rates (82.6% vs. 73.1%, P=0.506) did not differ significantly between the two groups. During the treatment period, the RBV dose reduction rate was significantly higher in group A than in group B (60.9% vs. 23.1%, P=0.01).
CONCLUSIONS
RBV dose reduction is performed frequently when patients are treated according to the current Korean guidelines. Given that lowering the RBV dose did not appear to decrease the virologic response during therapy, reducing RBV doses below the current Korean guideline may be effective for treatment, especially in low-weight patients.

Keyword

Ribavirin; Pegylated interferon alpha-2b; Chronic hepatitis C; Sustained virologic response; Koreans

MeSH Terms

Antiviral Agents/pharmacology/*therapeutic use
Body Mass Index
Body Weight
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
Genotype
Hepacivirus/drug effects
Hepatitis C, Chronic/*drug therapy/virology
Humans
Interferon-alpha/pharmacology/*therapeutic use
Male
Polyethylene Glycols/pharmacology/*therapeutic use
RNA, Viral/analysis
Recombinant Proteins/pharmacology/therapeutic use
Retrospective Studies
Ribavirin/pharmacology/*therapeutic use
Sex Factors
Treatment Outcome
Full Text Links
  • CMH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr